"Clavulanic Acids" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Acids, salts, and derivatives of clavulanic acid (C8H9O5N). They consist of those beta-lactam compounds that differ from penicillin in having the sulfur of the thiazolidine ring replaced by an oxygen. They have limited antibacterial action, but block bacterial beta-lactamase irreversibly, so that similar antibiotics are not broken down by the bacterial enzymes and therefore can exert their antibacterial effects.
Descriptor ID |
D002969
|
MeSH Number(s) |
D02.065.589.099.374 D03.633.100.300.374
|
Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Clavulanic Acids".
Below are MeSH descriptors whose meaning is more specific than "Clavulanic Acids".
This graph shows the total number of publications written about "Clavulanic Acids" by people in this website by year, and whether "Clavulanic Acids" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
Year | Major Topic | Minor Topic | Total |
---|
1995 | 0 | 1 | 1 |
1996 | 0 | 1 | 1 |
1999 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Clavulanic Acids" by people in Profiles.
-
Effect of topical antibiotic therapy on recovery after tonsillectomy in adults. Otolaryngol Head Neck Surg. 1999 Sep; 121(3):277-82.
-
Effectiveness of five days of therapy with cefuroxime axetil suspension for treatment of acute otitis media. Pediatr Infect Dis J. 1996 Feb; 15(2):157-64.
-
Clinical comparison of cefuroxime axetil suspension and amoxicillin/clavulanate suspension in the treatment of pediatric patients with acute otitis media with effusion. Clin Ther. 1995 Sep-Oct; 17(5):838-51.
-
Reversal of clavulanate resistance conferred by a Ser-244 mutant of TEM-1 beta-lactamase as a result of a second mutation (Arg to Ser at position 164) that enhances activity against ceftazidime. Antimicrob Agents Chemother. 1994 May; 38(5):1134-9.